ES2711427T8 - Lactobacillus reuteri ATCC PTA 6475 para su uso en la prevención o el tratamiento de la pérdida ósea en mamíferos - Google Patents

Lactobacillus reuteri ATCC PTA 6475 para su uso en la prevención o el tratamiento de la pérdida ósea en mamíferos

Info

Publication number
ES2711427T8
ES2711427T8 ES13800449T ES13800449T ES2711427T8 ES 2711427 T8 ES2711427 T8 ES 2711427T8 ES 13800449 T ES13800449 T ES 13800449T ES 13800449 T ES13800449 T ES 13800449T ES 2711427 T8 ES2711427 T8 ES 2711427T8
Authority
ES
Spain
Prior art keywords
mammals
prevention
treatment
bone loss
atcc pta
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES13800449T
Other languages
English (en)
Other versions
ES2711427T3 (es
Inventor
Eamonn Connolly
Robert Allen Britton
Laura Rae Mccabe
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Biogaia AB
Michigan State University MSU
Original Assignee
Biogaia AB
Michigan State University MSU
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogaia AB, Michigan State University MSU filed Critical Biogaia AB
Application granted granted Critical
Publication of ES2711427T3 publication Critical patent/ES2711427T3/es
Publication of ES2711427T8 publication Critical patent/ES2711427T8/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66Microorganisms or materials therefrom
    • A61K35/74Bacteria
    • A61K35/741Probiotics
    • A61K35/744Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/747Lactobacilli, e.g. L. acidophilus or L. brevis
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23LFOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/135Bacteria or derivatives thereof, e.g. probiotics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/59Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20Bacteria; Culture media therefor
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6888Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms
    • C12Q1/689Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms for bacteria
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23VINDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00Food compositions, function of food ingredients or processes for food or foodstuffs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K2035/11Medicinal preparations comprising living procariotic cells
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/156Polymorphic or mutational markers
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/16Primer sets for multiplex assays
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12RINDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
    • C12R2001/00Microorganisms ; Processes using microorganisms
    • C12R2001/01Bacteria or Actinomycetales ; using bacteria or Actinomycetales
    • C12R2001/225Lactobacillus

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Mycology (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Analytical Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Nutrition Science (AREA)
  • Polymers & Plastics (AREA)
  • Food Science & Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Physics & Mathematics (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
ES13800449T 2012-06-04 2013-06-04 Lactobacillus reuteri ATCC PTA 6475 para su uso en la prevención o el tratamiento de la pérdida ósea en mamíferos Active ES2711427T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261689338P 2012-06-04 2012-06-04
PCT/SE2013/050646 WO2013184064A1 (en) 2012-06-04 2013-06-04 Selection and use of lactic acid bacteria preventing bone loss in mammals

Publications (2)

Publication Number Publication Date
ES2711427T3 ES2711427T3 (es) 2019-05-03
ES2711427T8 true ES2711427T8 (es) 2019-06-20

Family

ID=49712339

Family Applications (2)

Application Number Title Priority Date Filing Date
ES18202594T Active ES2847424T3 (es) 2012-06-04 2013-06-04 Bacterias del ácido láctico para su uso en la prevención o el tratamiento de la pérdida ósea en mamíferos
ES13800449T Active ES2711427T3 (es) 2012-06-04 2013-06-04 Lactobacillus reuteri ATCC PTA 6475 para su uso en la prevención o el tratamiento de la pérdida ósea en mamíferos

Family Applications Before (1)

Application Number Title Priority Date Filing Date
ES18202594T Active ES2847424T3 (es) 2012-06-04 2013-06-04 Bacterias del ácido láctico para su uso en la prevención o el tratamiento de la pérdida ósea en mamíferos

Country Status (17)

Country Link
US (4) US20150150917A1 (es)
EP (2) EP2854826B9 (es)
JP (1) JP6193981B2 (es)
KR (2) KR102191537B1 (es)
CN (1) CN104755091B (es)
AU (2) AU2013272330B2 (es)
CA (1) CA2875841C (es)
DK (2) DK2854826T3 (es)
ES (2) ES2847424T3 (es)
HK (1) HK1211847A1 (es)
HR (1) HRP20190162T1 (es)
HU (1) HUE042643T2 (es)
LT (1) LT2854826T (es)
PL (2) PL2854826T3 (es)
SI (1) SI2854826T1 (es)
TR (1) TR201901771T4 (es)
WO (1) WO2013184064A1 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101915904B1 (ko) 2016-08-12 2018-11-06 한국식품연구원 락토바실러스 인테스티날리스를 포함하는 갱년기 예방 또는 치료용 조성물
KR102120479B1 (ko) * 2018-10-30 2020-06-09 주식회사 종근당바이오 프로바이오틱스를 유효 성분으로 포함하는 이차성 골다공증의 예방 또는 치료용 조성물
BR112021015321A2 (pt) * 2019-02-05 2021-10-05 Elanco Us Inc. Plataforma de dispensação viva, cassete de expressão, sequência de ácido nucleico, biomolécula, atividade anti-infecciosa, anticorpo, e, método para reduzir a colonização de um animal por uma bactéria patogênica
KR102080498B1 (ko) * 2019-08-23 2020-02-24 정영옥 페룰산 및 유산균을 유효성분으로 포함하는 골감소증 개선 또는 예방용 식품 조성물
WO2021112041A1 (ja) * 2019-12-02 2021-06-10 雪印メグミルク株式会社 骨強化剤
CN111718903A (zh) * 2020-06-24 2020-09-29 江南大学 一种筛选可预防和/或治疗骨质疏松的药物的方法
CN114711429B (zh) * 2021-06-08 2023-11-17 青岛蔚蓝生物股份有限公司 一株具有增强骨健康作用的罗伊氏乳杆菌及其应用
CN114634901B (zh) * 2022-05-18 2022-08-30 微康益生菌(苏州)股份有限公司 一种促进骨骼健康的干酪乳杆菌lc16及其培养方法与应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003105893A2 (en) * 2002-06-13 2003-12-24 Alimentary Health Limited Probiotic therapies
US7344867B2 (en) * 2005-04-15 2008-03-18 Eamonn Connolly Selection and use of lactic acid bacteria for reducing inflammation in mammals
KR20140043145A (ko) * 2005-07-26 2014-04-08 네스텍 에스.아. 항비만제 및 항비만 식품
EP2061483A1 (en) * 2006-09-07 2009-05-27 McGill University Oral polymeric membrane feruloyl esterase producing bacteria formulation
US20080254011A1 (en) * 2007-04-11 2008-10-16 Peter Rothschild Use of selected lactic acid bacteria for reducing atherosclerosis

Also Published As

Publication number Publication date
DK3456334T3 (da) 2021-01-25
US9968643B2 (en) 2018-05-15
CN104755091A (zh) 2015-07-01
US20180200313A1 (en) 2018-07-19
US20190142879A1 (en) 2019-05-16
CA2875841C (en) 2021-02-02
US20150150917A1 (en) 2015-06-04
JP2015526389A (ja) 2015-09-10
LT2854826T (lt) 2019-02-11
ES2847424T3 (es) 2021-08-03
EP2854826A1 (en) 2015-04-08
CN104755091B (zh) 2020-07-21
EP3456334B1 (en) 2020-11-11
KR20200044134A (ko) 2020-04-28
HRP20190162T1 (hr) 2019-04-05
HK1211847A1 (en) 2016-06-03
US10232001B2 (en) 2019-03-19
US10537598B2 (en) 2020-01-21
JP6193981B2 (ja) 2017-09-06
AU2018200524B2 (en) 2019-07-18
PL2854826T3 (pl) 2019-06-28
PL3456334T3 (pl) 2021-05-04
SI2854826T1 (sl) 2019-03-29
HUE042643T2 (hu) 2019-07-29
AU2013272330B2 (en) 2017-11-02
TR201901771T4 (tr) 2019-03-21
EP2854826B1 (en) 2018-11-14
AU2013272330A1 (en) 2015-01-15
EP3456334A1 (en) 2019-03-20
WO2013184064A1 (en) 2013-12-12
EP2854826B9 (en) 2019-05-08
KR20150028968A (ko) 2015-03-17
CA2875841A1 (en) 2013-12-12
ES2711427T3 (es) 2019-05-03
DK2854826T3 (en) 2019-03-11
US20170128501A1 (en) 2017-05-11
AU2018200524A1 (en) 2018-02-15
EP2854826A4 (en) 2016-07-06
KR102191537B1 (ko) 2020-12-16

Similar Documents

Publication Publication Date Title
ES2711427T8 (es) Lactobacillus reuteri ATCC PTA 6475 para su uso en la prevención o el tratamiento de la pérdida ósea en mamíferos
CL2015000331A1 (es) Compuestos derivados de piridazina 1,4-disustitutidos; composicion y combinacion farmaceutica que los comprende y uso en el tratamiento de la atrofia muscular espinal.
CO7020879A2 (es) Miméticos de apelina sintéticos para el tratamiento de insuficiencia cardíaca
CO6801724A2 (es) Composiciones y métodos para el tratamiento de la mielofibrosis
EP2981274A4 (en) Probiotic strains for use in treatment or prevention of osteoporosis
SMT201600182B (it) Ligandi sigma per l'uso nella prevenzione e/o nel trattamento del dolore post-operatorio
ZA201304638B (en) Composition for use in the prevention and /or treatment of skin condition and skin diseases.
BR112015001712A2 (pt) uso de s-pindolol para o tratamento da caquexia e sarcopenia
BRPI0912687A2 (pt) uso de bactéria probiótica para o tratamento de hiperhomocisteinaemia
BR112013034055A2 (pt) alcaftadina para uso no tratamento de urticária
CL2008000110A1 (es) Uso de compuestos derivados de piranona sustituidos para el tratamiento del sindrome metabolico; y compuestos derivados de piranona sustituidos.
BR112014009456A2 (pt) uso de melatonina para o tratamento e/ou prevenção de mucosite
CL2012003322A1 (es) Compuestos derivados de benzamida sustituidas; composicion farmacéutica; y uso en el tratamiento del cancer.
CL2016002151A1 (es) Derivados de piridazina para uso en la prevención o el tratamiento de un trastorno atáxico
DK3442547T3 (da) Lactobacillus reuteri MM4-1A til anvendelse i behandling eller forebyggelse af autismespektrumforstyrrelser
MX359181B (es) Hidrolizado de colágeno y uso del mismo.
CL2015000537A1 (es) Siarn y su uso en los métodos y composiciones para el tratamiento y/o prevención de enfermedades de los ojos.
CL2013001313A1 (es) Composicion que comprende microorganismos probióticos no replicantes para prevenir o tratar infecciones gastrointestinales
CL2015001458A1 (es) Composición simbiotica y el uso de la misma.
ES2663096T3 (es) Métodos para el tratamiento del síndrome nefrótico y de afecciones relacionadas
ES2660372T8 (es) Sustancias y procedimientos para la utilización en la prevención y/o el tratamiento en la enfermedad de Huntington
ES2445016B1 (es) Vacuna para el tratamiento/la prevencion de escuticociliatosis en peces
GB2524474B (en) Composition and use of lactobacillus reuteri GMNL-89 in treating type 2 diabetes
GB201208850D0 (en) Tri-subsituted glycerol compounds for use in the treatment of clinically isolated syndrome and/or multiple sclerosis
CL2015001397A1 (es) Compuestos derivados de 4-amino-7,8-dihidropirimido[5,4-f][1,4]oxazepin-5(6h)-ona, inhibidores de diacilglicerol aciltransferasa; composicion farmaceutica y el uso en el tratamiento de la obesidad.